Abbott Laboratories (NYSE: ABT) is ranked among the best low volatility stocks to buy according to analysts. RBC Capital maintained an Outperform rating on ABT and raised its price target to $147, citing strong revenue and EPS growth potential in the medical technology industry.

RBC Capital’s intra-quarter checks show positive healthcare utilization for Abbott Laboratories (NYSE: ABT) in Q2. The firm highlights growth catalysts like the diabetes brand and the less elective nature of ABT’s medical device portfolio, attracting investor interest.

RBC Capital continues to see Abbott Laboratories (NYSE: ABT) as the best-performing large cap in its coverage year-to-date. The firm notes positive trends in diabetes care, diagnostics, nutrition, and established pharmaceuticals as factors supporting ABT’s performance.

Abbott Laboratories (NYSE: ABT) is a leading global healthcare company producing branded generic medications, medical devices, diagnostics, and nutritional products. The company is recognized for its diverse portfolio in the healthcare industry.

While ABT shows investment potential, some AI stocks may offer greater upside with less downside risk. Investors seeking undervalued AI stocks can explore opportunities that benefit from current economic trends and tariffs. For more information, refer to the best short-term AI stock report.

Disclosure: None.

Read more at Yahoo Finance: RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)